Inovio Stock Analysis


USD 2.04  0.11  5.70%   

Inovio Pharma price slide over the last few months may raise some interest from institutional investors. The stock closed today at a share price of 2.04 on 10,235,497 in trading volume. The company directors and management were not very successful in positioning the firm resources to exploit market volatility in October. However, diversifying your holdings with Inovio Pharma or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.2. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Inovio Pharma partners.
Please see Risk vs Return Analysis.
The Inovio Pharma stock analysis report makes it easy to digest most publicly released information about Inovio Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Inovio Stock analysis module also helps to analyze the Inovio Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Inovio Stock Analysis Notes

About 46.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.78. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inovio Pharma recorded a loss per share of 1.07. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 6th of June 2014. Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus , cancer, and infectious diseases. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Inovio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 317 people. To learn more about Inovio Pharma call Joseph Kim at 267 440-4200 or check out

Inovio Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Inovio Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Inovio Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Inovio Pharma generated a negative expected return over the last 90 days
Inovio Pharma has high historical volatility and very poor performance
Inovio Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 2.11 M. Reported Net Loss for the year was (354.69 M) with loss before taxes, overhead, and interest of (247.47 M).
Inovio Pharma has about 348.13 M in cash with (196.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4.
Inovio Pharma has a frail financial position based on the latest SEC disclosures
Latest headline from INOVIO Provides an Update on Lassa Fever and MERS Programs -

Inovio Pharma Upcoming and Recent Events

Earnings reports are used by Inovio Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inovio Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of March 2022
Next Financial Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Inovio Largest EPS Surprises

Earnings surprises can significantly impact Inovio Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Inovio Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Inovio Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Inovio Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Inovio Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
9th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
19th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Cost Associated with Exit or Disposal Activities
17th of May 2022
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
11th of April 2022
Unclassified Corporate Event
11th of February 2022
Unclassified Corporate Event
10th of February 2022
Unclassified Corporate Event

Inovio Pharma Thematic Classifications

In addition to having Inovio Pharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Aggressive Defence
Small capitalization, high growth potential companies
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Inovio Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Inovio Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inovio Pharma backward and forwards among themselves. Inovio Pharma's institutional investor refers to the entity that pools money to purchase Inovio Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares27.4 K47 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares27.4 K98 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares27.4 K137 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares19.5 K140 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares19.5 K181 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares23 K214 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares23 K204 K
Note, although Inovio Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Inovio Market Capitalization

The company currently falls under 'Small-Cap' category with total capitalization of 406.04 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inovio Pharma's market, we take the total number of its shares issued and multiply it by Inovio Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Inovio Profitablity

Inovio Pharma's profitability indicators refer to fundamental financial ratios that showcase Inovio Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Inovio Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Inovio Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Inovio Pharma's profitability requires more research than a typical breakdown of Inovio Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(67.35) (72.67) 
Return on Average Assets(58.64) (63.27) 
Return on Average Equity(70.55) (76.12) 
Return on Invested Capital(0.65) (0.70) 
Return on Sales(170.01) (174.48) 

Management Efficiency

The entity has Return on Asset of (40.59) % which means that on every $100 spent on asset, it lost $40.59. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (87.99) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharma management efficiency ratios could be used to measure how well inovio pharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -72.67. The value of Return on Average Assets is estimated to slide to -63.27. Inovio Pharma Revenue to Assets are quite stable at the moment as compared to the past year. The company's current value of Revenue to Assets is estimated at 0.003673. Asset Turnover is expected to rise to 0.003517 this year, although the value of Total Assets Per Share will most likely fall to 2.05.
Last ReportedProjected for 2022
Book Value per Share 1.91  1.92 
Enterprise Value over EBIT(3.00) (3.24) 
Enterprise Value over EBITDA(3.42) (3.69) 
Price to Book Value 2.63  2.70 
Tangible Assets Book Value per Share 2.31  2.33 
Enterprise ValueB827.4 M
Tangible Asset Value482.8 M520.9 M

Technical Drivers

As of the 30th of November, Inovio Pharma retains the risk adjusted performance of (0.028322), and Market Risk Adjusted Performance of (0.06). Inovio Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Inovio Pharma, which can be compared to its competitors. Please check out Inovio Pharma standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Inovio Pharma is priced fairly, providing market reflects its last-minute price of 2.04 per share. Please also validate Inovio Pharma total risk alpha, which is currently at (0.41) to confirm the company can sustain itself at a future point.

Inovio Pharma Price Movement Analysis

The output start index for this execution was fifty-nine with a total number of output elements of two. The Triangular Moving Average shows Inovio Pharma double smoothed mean price over a specified number of previous prices (i.e., averaged twice).

Inovio Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inovio Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inovio Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inovio Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Weiner over three months ago via Macroaxis 
Exercise or conversion by David Weiner of 11875 shares of Inovio Pharma subject to Rule 16b-3
Simon Benito over three months ago via Macroaxis 
Exercise or conversion by Simon Benito of 2000 shares of Inovio Pharma subject to Rule 16b-3
Sumner Michael John over three months ago via Macroaxis 
Acquisition by Sumner Michael John of 105000 shares of Inovio Pharma subject to Rule 16b-3
Ann Miller over six months ago via Macroaxis 
Acquisition by Ann Miller of 28000 shares of Inovio Pharma subject to Rule 16b-3
Shepard Jay over six months ago via Macroaxis 
Exercise or conversion by Shepard Jay of 18000 shares of Inovio Pharma subject to Rule 16b-3
Jacqueline Shea over six months ago via Macroaxis 
Acquisition by Jacqueline Shea of 198000 shares of Inovio Pharma subject to Rule 16b-3
Jacqueline Shea over six months ago via Macroaxis 
Exercise or conversion by Jacqueline Shea of 16666 shares of Inovio Pharma subject to Rule 16b-3
Ann Miller over six months ago via Macroaxis 
Exercise or conversion by Ann Miller of 4273 shares of Inovio Pharma subject to Rule 16b-3
Simon Benito over six months ago via Macroaxis 
Exercise or conversion by Simon Benito of 2000 shares of Inovio Pharma subject to Rule 16b-3
Jacqueline Shea over six months ago via Macroaxis 
Exercise or conversion by Jacqueline Shea of 59737 shares of Inovio Pharma subject to Rule 16b-3
Laurent Humeau over six months ago via Macroaxis 
Exercise or conversion by Laurent Humeau of 19900 shares of Inovio Pharma subject to Rule 16b-3
Jacqueline Shea over six months ago via Macroaxis 
Acquisition by Jacqueline Shea of 210700 shares of Inovio Pharma subject to Rule 16b-3

Inovio Pharma Predictive Daily Indicators

Inovio Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Inovio Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Inovio Pharma Forecast Models

Inovio Pharma time-series forecasting models is one of many Inovio Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inovio Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Inovio Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Inovio Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Inovio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Inovio Pharma. By using and applying Inovio Stock analysis, traders can create a robust methodology for identifying Inovio entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(78.27) (84.45) 
EBITDA Margin(65.74) (70.93) 
Gross Margin 0.90  0.89 
Profit Margin(64.75) (69.86) 

Current Inovio Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inovio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inovio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Inovio Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Inovio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Inovio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Inovio Pharma, talking to its executives and customers, or listening to Inovio conference calls.
Inovio Analyst Advice Details

Inovio Stock Analysis Indicators

Inovio Pharma stock analysis indicators help investors evaluate how Inovio Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Inovio Pharma shares will generate the highest return on investment. By understating and applying Inovio Pharma stock analysis, traders can identify Inovio Pharma position entry and exit signals to maximize returns.
Quick Ratio2.74
Fifty Two Week Low1.3800
Revenue Growth187.50%
Shares Short Prior Month45.73M
Average Daily Volume Last 10 Day5.48M
Average Daily Volume In Three Month5.77M
Shares Percent Shares Out18.27%
Short Percent Of Float18.55%
Forward Price Earnings-1.87
Float Shares245.5M
Fifty Two Week High7.3300
Enterprise Value To Ebitda-0.52
Fifty Day Average1.9344
Two Hundred Day Average2.3781
Enterprise Value To Revenue83.48
Please see Risk vs Return Analysis. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for analysis

When running Inovio Pharma price analysis, check to measure Inovio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharma is operating at the current time. Most of Inovio Pharma's value examination focuses on studying past and present price action to predict the probability of Inovio Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inovio Pharma's price. Additionally, you may evaluate how the addition of Inovio Pharma to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Inovio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharma. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
481.5 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Inovio Pharma is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharma's value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharma's market value can be influenced by many factors that don't directly affect Inovio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Inovio Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.